Related Experiment Video
Updated: Aug 8, 2026

Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis
Ivana Crnic1, Karin Strittmatter, Ugo Cavallaro
1Institute of Biochemistry and Genetics, Department of Clinical-Biological Sciences, University of Basel, Basel, Switzerland.
Abstract:
Reduced expression of neural cell adhesion molecule (NCAM) has been implicated in the progression to tumor malignancy in cancer patients. Previously, we have shown that the loss of NCAM function causes the formation of lymph node metastasis in a transgenic mouse model of pancreatic beta cell carcinogenesis (Rip1Tag2). Here we show that tumors of NCAM-deficient Rip1Tag2 transgenic mice exhibit up-regulated expression of the lymphangiogenic factors vascular endothelial growth factor (VEGF)-C and -D (17% in wild-type versus 60% in NCAM-deficient Rip1Tag2 mice) and, with it, increased lymphangiogenesis (0% in wild-type versus 19% in NCAM-deficient Rip1Tag2 mice). Repression of VEGF-C and -D function by adenoviral expression of a soluble form of their cognate receptor, VEGF receptor-3, results in reduced tumor lymphangiogenesis (56% versus 28% in control versus treated mice) and lymph node metastasis (36% versus 8% in control versus treated mice). The results indicate that the loss of NCAM function causes lymph node metastasis via VEGF-C- and VEGF-D-mediated lymphangiogenesis. These results also establish Rip1Tag2;NCAM-deficient mice as a unique model for stochastic, endogenous tumor lymphangiogenesis and lymph node metastasis in immunocompetent mice.
Insights
Loss of neural cell adhesion molecule (NCAM) promotes tumor spread by increasing lymphangiogenesis via VEGF-C and VEGF-D. This study identifies a new mouse model for cancer metastasis research.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Reduced neural cell adhesion molecule (NCAM) expression is linked to cancer progression.
- NCAM loss promotes lymph node metastasis in a pancreatic beta cell cancer model.
Purpose of the Study:
- To investigate the mechanism by which NCAM deficiency drives lymph node metastasis.
- To explore the role of lymphangiogenic factors in NCAM-deficient tumors.
Main Methods:
- Utilized a transgenic mouse model (Rip1Tag2) deficient in NCAM.
- Analyzed expression of vascular endothelial growth factor (VEGF)-C and -D.
- Assessed lymphangiogenesis and lymph node metastasis.
- Employed adenoviral expression of soluble VEGF receptor-3 to inhibit VEGF-C/D function.
Main Results:
- NCAM-deficient tumors showed significantly higher expression of VEGF-C and -D (60% vs. 17%) and increased lymphangiogenesis (19% vs. 0%).
- Inhibition of VEGF-C/D function reduced tumor lymphangiogenesis (28% vs. 56%) and lymph node metastasis (8% vs. 36%).
Conclusions:
- NCAM loss drives lymph node metastasis through enhanced VEGF-C and VEGF-D-mediated lymphangiogenesis.
- The Rip1Tag2;NCAM-deficient mouse is a valuable model for studying endogenous tumor lymphangiogenesis and metastasis.
Related Concept Videos
The Tumor Microenvironment
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Cell Migration through Invadopodia
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

